0001193125-24-247643.txt : 20241030 0001193125-24-247643.hdr.sgml : 20241030 20241030165652 ACCESSION NUMBER: 0001193125-24-247643 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241030 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241030 DATE AS OF CHANGE: 20241030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CalciMedica, Inc. CENTRAL INDEX KEY: 0001534133 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 452120079 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39538 FILM NUMBER: 241411164 BUSINESS ADDRESS: STREET 1: 505 COAST BOULEVARD SOUTH STREET 2: SUITE 307 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-952-5500 MAIL ADDRESS: STREET 1: 505 COAST BOULEVARD SOUTH STREET 2: SUITE 307 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: CalciMedica, Inc. /DE/ DATE OF NAME CHANGE: 20230322 FORMER COMPANY: FORMER CONFORMED NAME: GRAYBUG VISION, INC. DATE OF NAME CHANGE: 20170717 FORMER COMPANY: FORMER CONFORMED NAME: GRAYBUG, Inc. DATE OF NAME CHANGE: 20150303 8-K 1 d894566d8k.htm 8-K 8-K
NASDAQ false 0001534133 0001534133 2024-10-30 2024-10-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2024

 

 

CalciMedica, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39538   45-2120079

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

505 Coast Boulevard South, Suite 307
La Jolla, California		     92037
(Address of principal executive offices)     (Zip Code)

Registrant’s telephone number, including area code: (858) 952-5500

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.0001, par value per share   CALC   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition

Based on current estimates, as of September 30, 2024, CalciMedica, Inc. (the “Company” or “CalciMedica”) had cash, cash equivalents and short-term investments of $14.6 million.

These estimates are preliminary, unaudited and are subject to change upon completion of the Company’s financial statement closing procedures. The review of the Company’s financial statements for the three and nine months ended September 30, 2024 is ongoing and could result in changes to these amounts.

The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to these preliminary results and, accordingly, does not express an opinion or any other form of assurance about them.

The Company expects to file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 on or about November 14, 2024.

 

Item 8.01

Other Events

Suspension of offering under Sales Agreement

On October 30, 2024, the Company issued a press release announcing the commencement of a proposed underwritten public offering of its common stock. A copy of the press release is attached hereto as Exhibit 99.1.

In connection with the Company’s proposed public offering, the Company suspended and, during the duration of the proposed public offering, is not offering any shares of its common stock pursuant to the prospectus filed with the Securities and Exchange Commission (the “SEC”) on August 11, 2023, as amended by the prospectus supplement filed with the SEC on March 29, 2024, relating to the At the Market Offering Agreement, dated August 11, 2023 (the “Sales Agreement”), by and between the Company and H.C. Wainwright & Co., LLC. The Company will not make any sales of common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the SEC; however, the Sales Agreement remains in full force and effect.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, which is being made only by means of a written prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”) nor shall there be any sale of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

The information contained in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The information contained in Exhibit 99.1 shall not be incorporated by reference into any filing we make with the SEC, whether before or after the date hereof, regardless of any general incorporation language in such filing.

Cautionary Statement Regarding Forward Looking Statements

Any statements in this Current Report on Form 8-K about future expectations, plans and prospects for CalciMedica, including statements about the timing, terms and completion of the underwritten public offering, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: CalciMedica’s inability, or the inability of underwriters, to satisfy the conditions to closing for the proposed underwritten public offering; and economic, business, competitive, and/or regulatory factors affecting the business of

 

1

CalciMedica generally. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” in CalciMedica’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 12, 2024, and other filings CalciMedica makes with the SEC from time to time and available at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. CalciMedica undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

The forward-looking statements included in this Current Report on Form 8-K are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.

   

Description

99.1    Press release dated October 30, 2024.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CalciMedica, Inc.
Date: October 30, 2024     By:  

/s/ A. Rachel Leheny, Ph.D.

    Name:   A. Rachel Leheny, Ph.D.
    Title:   Chief Executive Officer
 EX-99.1 2 d894566dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

CalciMedica Announces Proposed Public Offering of Common Stock

LA JOLLA, Calif., October 30, 2024 /PRNewswire/ — CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (“CRAC”) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it has commenced an underwritten public offering of its shares of common stock.

All of the shares to be sold in the underwritten public offering are to be sold by the Company. In connection with the proposed offering, the Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Jones is acting as the sole book-running manager for the offering.

The underwritten public offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-273949) (including a base prospectus) previously filed with the Securities and Exchange Commission (the “SEC”) on August 11, 2023 and declared effective by the SEC on August 18, 2023. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the underwritten public offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, electronic copies of the preliminary prospectus supplement and the accompanying prospectus relating to the underwritten public offering may also be obtained by contacting: JonesTrading Institutional Services LLC, Attention: Equity Capital Markets, 325 Hudson Street, 6th Floor New York, New York 10013; email: ecm@jonestrading.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About CalciMedica

CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica’s proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica’s lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with AP with SIRS and completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with AKI with associated AHRF with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in patients with AIPT with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for CalciMedica, including statements about the timing, terms and completion of the underwritten public offering, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: CalciMedica’s inability, or the inability of the underwriter, to satisfy the conditions to closing for the proposed underwritten public offering; and economic, business, competitive, and/or regulatory factors affecting the business of CalciMedica generally. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” in CalciMedica’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the SEC on August 12, 2024, and other filings CalciMedica makes with the SEC from time to time and available at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. CalciMedica undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

CalciMedica Contact:

Investors and Media

Argot Partners

Sarah Sutton/Kevin Murphy

calcimedica@argotpartners.com

(212) 600-1902

EX-101.SCH 3 calc-20241030.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 calc-20241030_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 calc-20241030_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g894566g1030074957425.jpg GRAPHIC begin 644 g894566g1030074957425.jpg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htm IDEA: XBRL DOCUMENT v3.24.3
Document and Entity Information
Oct. 30, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001534133
Document Type 8-K
Document Period End Date Oct. 30, 2024
Entity Registrant Name CalciMedica, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39538
Entity Tax Identification Number 45-2120079
Entity Address, Address Line One 505 Coast Boulevard South
Entity Address, Address Line Two Suite 307
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code (858)
Local Phone Number 952-5500
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001, par value per share
Trading Symbol CALC
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports calc-20241030.xsd calc-20241030_lab.xml calc-20241030_pre.xml d894566d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d894566d8k.htm": { "nsprefix": "calc", "nsuri": "http://www.calcimedica.com/20241030", "dts": { "schema": { "local": [ "calc-20241030.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "calc-20241030_lab.xml" ] }, "presentationLink": { "local": [ "calc-20241030_pre.xml" ] }, "inline": { "local": [ "d894566d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-10-30_to_2024-10-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d894566d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-10-30_to_2024-10-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d894566d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.calcimedica.com//20241030/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001193125-24-247643-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-247643-xbrl.zip M4$L#!!0 ( !F'7EGECO;V/@, %<+ 1 8V%L8RTR,#(T,3 S,"YX MN9;^:;G\[AQ[M*P@T:*[0:1UF21H"JT*50\W'4V)C; M0HCHX]'K5X=OXAB.3T[/(89KYVJ;,W9[>YN4,Z&LEHTC"S8I=,4@CGO]SY=7 M\$]K/8<)2N06H>+6H8&_&B'+?"_=>Y>EZ8=D-(09Y-X>E-QA#EG*1BGSFI!E M>3;*]S/X]A6^!#L*+D6%0["N%T;,KQV\+?Z @#K62J&4N( 3H;@J!)=PT7/^ M$TY5D< G*6'B89:(6C0W6":=U3M;YK:XQHJ_?@5 &5,V5V2RJ<:13T67B;NI MD8DV#R.O30=,>H*1ZG& 40* M]=\6A!=/J4&&3AY ;DZ<$=/&X8DVU3'. M>",)U:C_&R[%3& 9M*A;*U1N16=5PW$S1W?.*[0U+_"IV::V>BPT8INQ?[^> M782.BXX\ " TH:AJ;1RTO7BFBS D6S+J?\5](6)_%6=[\2A+R%@$ZE'B&ZH( M[,5$^OH^B\BR.78F8CIJC[O7Y1[YHM[L%X//P_Y6Q^N;I/,:?'*EM N.ADQX M70LUT]T57?HFSOM.GN ,P@;+N2F,EKA]S[':Z!J-$[3J[X>A-7!M<#:._,J) M^SWS7?)I0GNF5WG@8'6\O)@1!.79/;T>ZX3SX#,O!B^G-Y/+I6G?#N/(4M[E M8#Q_<[BUP:>&2Q!+"SZ4;7/4WP9:3P[>^[DD#?"'J\GIUB=B^48PQ^^TTM6B MY7FLB\:_1/W_3ZK\HHC=XI2:RU2!602"'I,)J7_?27W)LV=:(GW'B=#!]#E& M?_29UUL8'KDJH34' WN';-W(NOW&8OFW.@IG'W@CEWGOP)W&-N!ZQ79'WC/; MC.MN^YKUD\S61[F[&8Y\>]6N'/KY U!+ P04 " 9AUY9$5_0;:X& "F M20 %0 &-A;&,M,C R-#$P,S!?;&%B+GAM;,V<;6_;-A#'WQ?H=[AY;S:@ M\N,&K$;3(G.2(5C2!(V[#1N&0I88AYA,&J0=%6D>[^ M=W_E=ZXLF7[W8;.(X)$(23D[Z0RZ_0X0%O"0LOE)9R4]7P:4=D#&/@O]B#-R MTMD2V?GP_O6K=]]Y'IQ=7'X$#Q[B>"G'O=YZO>Z&]Y1)'JUB)2F[ 5_TP//R M^,GT,_R1EAO#)Q(17Q)8^#(F GY=T2@<#_O#GP;]_B_=43%-$%_K0>C'9 R# M?F_4[^E(& S&@]'XYR'<7L-YHL-@2A>DF,R76T'G#S'\$/P(2=899XQ$$=G" M!64^"Z@?P5W>\QNX9$$73J,(/NDTJ1J51#R2L)NI1I3]-]9_S73[\/H5@#J/ M3";[3CKZ;&0G8S,349>+N6JV/^KE*9U=QN8@93U*$@9OW[[M)4>+T9*:8I7X MH/?7]=5=\$ 6OJ?.O_I]!5D92<+))B8L))GR5VT>9%$/ M@MRGJIJ^1%*2H#OGC[V04$W(2&]X>D-W^+WZX(B MWYF8..D8DGK[#>FX4Q'L:?DBR'74YA'_640OX.KWMHR]1#%/OQ=\8>PB*\<- M![]$L\C8IB9);>GY)LS[?'?,:RI4-":(Y"NA\*KSJTW\O$^4X9]<^]]WO5WM ME]*J>@F1Y*INOVY(WI%@)6B\/=\$#\HO^>@OB"V9YMR6 *TTPLMC7' MUT.B M-B\ >070)9S9;:[O(L)UFW<#^72A7J_5G_@B\N>V!#]):@E=<^O<<- %5H,0 M$J5?E4%+.]/90*-%+&V[=!+E^_VY(G_%@I>=FJKJW)7D_IR6 C8WS MPV,NN![J(%&:"X-6=D83O\TBD9:]XF!X2P3EX3D+S]0[\[H\/DEN&4RS%5X1 MA(&J01";V;0$J!J@BZ#AVT#K1HZM^\>X6/A$YE2_VV-QG3=AYMQ6+Q5*C/#R M&/<+!9,>[G7"K@+.F[#F^C9<)%@WCP'R)0NX6'*1W/.[B]7@3/A*7:1L)SRL MR?41J58QM[/)K5/A-3S&MU/ P&N/FX._A/M7 IU^J0RB,!C=VO@5ZKIC% G?J;RU!=+-%[ MFC[E>0ZUI2*M(GS,&K<(=H>[4AB7=%4*]FOAXC4"J*BW^F_R;? %T);AC6=4QC-@SH/\-+,^@/ M7=$?OCCTA[;H#YM ?_CMT)^N>6/H(]FP1K_2"R+Z$[5Y(Z9\S9X%?C'])6!O ML&."?A>&AOQ3R8: UV6 "]"%<&''-E"%NIT+1,R3]\,WXE;P1\J"FK=URC1> M O!EQDS4/XE%0]^HVQ#_Z8T-A4Y>#7<(&K%2-0DU_"".PRV7L1_]39?U[W&: M%5["*)A-F09A+Q)M# RJ#0U!6@E4**^-PBM_GWH=8+9MU U%_NCRZ?>"LYOWRP[R6 M@"PUP,W'7< T:R'!F8A#HHYUW["9?HN0UFG:#=0_!8UCPB9\L5BQ['ZDM*6U M)+DE9*NM\(H@%W@K!)$(SBK ?@EGBAMLO(ARW>X=EP[PB 8TIFQ^K:ZX!?4C M6Y9-F6TM&R@WP"Z/D@"HOD MDY!ZF9>XN;^WOW"H4F@)8PM3_%BD"];'5)'P5F6@6 ?20I!4<@:]:1-%X)_I M!!7]2RE71+@/@$'G98Q!N4'S,!S$(XY$B793@Y&6:W0^&G)4.26U;.&LC!P, M9U,:1[571>[R6EX1>6" FX]CK(3&@RYP&H20R,R4(95VIK*!1HM(VG:+\5CD M?$'$7!7[3?!U_*!>PY<^J[G^L42BU0C=3V@C("&S5P3%)]$R9=2%23?T-^N_"7&^+5<0C8EV@B,[^!79EL M]1<6\ T9,-%NXZ*XXTIMZ6\7RG;1]#MVU)[_ 5!+ P04 " 9AUY9PD?@ M?^$$ '+@ %0 &-A;&,M,C R-#$P,S!?<')E+GAM;-6:86_B-AC'WY]T MW\'+WFS20@BTVQ65GAAM3VBT1OKG^SO?)[7WOD?ADGJ8+W0J"U6I5BZ=,:,F7*8;4M4@F ?%] M6[\[_DA^WS;7(D/@0#60A.H4%/EUR7C<:M0;%V&]_J[6W)B6D*+1+6 M@V8],#5)&+;"9NNR008/Y"Z+(\B8); OEHN-8K-Y2GZ(?B29ZE8* 9S#AMPS M047$*"?N:]9%HU]'6UZRELTA]&67)/Z-;Y&0-\\FWU7Q3 MY(<-OQG6UCKV;DR3VZPJR6$(4V)>/PY[N38CRB-$&[.(9N,JV(X5' HI74LA MDTU@9,&MC)8)B-2^=D1\)U*6;GIB*E62=<8C65Y;D6>T^%N0$L$Y!Q!#;,*8#_UVG;[9L=P-8 M1KDDV"]Q!DY#5)O)YR &9EILFCL>JID4IBJ76OR);]2Q:#:7J-1PZG (PO%I*F$)1Y9 M:K0D%\8\Y>8:3$$IB/O;))PTFSG%:55#5O,;,^O@4(W-<+WG='8NK -1=2D= M&+5XFL[@VR!HKR'\]3Z-]B&+;9?G,&VG1N&,&.FHR(M\W!1 MK*TNM&*_EMD[QYCA8DZJA519:D>88>C*)4[QFZZ,2R+\0JBJ$_V"?0OXRC' M]XS#XS*9@"I'<<*'J%J+ M+KY]4F.Y$J\"N"]W!-^^90O/G15ZKBO9H]B3&BCYS,R&_6L('L5P!..1;\OR MTDV6 ZE3RO]BB_*KB^((CG \<&TINK,O8^:3C@):AEM>4UU2>9^6C3N;+^87 M2#Z82U%RG7>LJRZC8Z^6DSL;+G^@OQ1$5R;)4NR6.?I<6"?$U25VPK#%YLXV MRDAR%K&4B=D#WHP5,];._-FT0%E=8$5N=[0NW-E,&2@P0P[P:2G['<0<'U!/ MT^GYT^)+$:I+[R77EJ([>R@'O>EIO03U]2P+XCA#M,"[Y>K.QHH]F!$V)F.6 M\M('4#[KJLOMV*OEY,[NR5A1<\AQM$DF\NS;W8&HNH0.C%H\KNV/W"6@9MB/ M#TJNTCG.%0LJ2AX_.1&BNNA>M&U!NK8Y6:S(:(PJ%@ M"( X !D.#DT-38V9#AK+FAT;>U=[5/CMM;_SE^A26]O829O3@)+ LL= MFLVVW+) "9UVGB\=Q5:(BF.YDDV2^]<_YTBRXS@.!$A@]UXZTR6Q9>GHO/[. MD>0<_VLZ]LD]DXJ+X.,/3K7^ V&!*SP>W'[\X;3?/3O[X5\G.\>C")I!TT!U M/,8_ED91%'9JM>E ^E7%W.JMN*_!C5JCWFB6;,-85:)9R%3:>DC5H"KD;2VY ML] \$$$0C]/&D\FDJKO'![Q(UO")&C2J0"LFN9L\-_5Y<+?PV*2I'W+:[79- MWTV:+K5,!VC4Z\T:WAY0Q9+F+O7=A>9X@8^9QUU:=<48R6\Y]68])47Q(D*@ M3AER)5L/Y\, ,;(OT@>FJM@ZT M#6"^[(\?K\_GS:/B]O.FM4C20 V%'-,(- 9[VJ_4&Y7&0::3"FC$0D>)ACS6 MSV&EZ:2\A,'Y0U/-<1'O>CG-M(T/:N:F;;I:5U#+2ZCMC'KP)^*1STX.*[\< MU\S'G>,QBRC!QROL[YC??RQU11"Q(*K<@':6B&N^?2Q%;!K5='*IF.B2$ M' ^$-SLY]O@]4=',9Q]+'E>A3V>H_JQT0H[YM(.MF;2?N>>QP'R&)A=&]PGW M/I9^UK?^!+/[L\_<6/)HUINZ(QK?WCYU-#U# M/KVO--H'I9,A]15[;.0<3WH!"&W6A?$E]<\"CTU_8;,L4U8T>")7ZF#<^\V6 MTVPNTU?+"5"R(9/@7IF"[^AM.DJ[!!AKF\Y,CX3N\V-)\7'HI]=&$B>)7JV2 MN++J5'G);2I=*5!''Q^D9F>[,$/]78E8FJ_:HCN6O5I::[ W>8QI8:5?N8<7 MAIQ)HEG("OU-]^R710'E'T:J"_L/08+"2[^"JY'1)QJQDSEMR9/S>W-:O15M MDSOIL.DXM07NI-R<-.H?5 M?1X<9=KZ;!@=C:F\Y4$%/W<(C2.17)'\=F0O87=ATAEZ\_J^K_2R3^_U<-5 S<<':CQ[ MH$RW+>B$+$^ #$$T%<7_PSK.8?I]2,?T<%XOGMXNRF]XGT;TYO>OW5Y-1?B9Q^K_O;]=G-6:]/3B\^D=X?W9]/+W[J MD>[EER]G_?[9Y<6+:&QL@L;?3_L_GUW\='-Y42:?JMTJ:=3W6^T<7?-!#]=0 MS$5]>,R@"A7SX%F*6:U#LT7=/#)&VG"^7Y[\FD8ZGTSB(XKD=?A*.O7Y\OH+ M.58A#5(W-.(1J\ 5ET&HG$@:EDY6 HA/PHT1/V2PU=/Q0[/^H60PW&)T/JXA M72?ORK,%Y=F(L8,[NNY=W)#KWM7E]IG&.8TB9#$ MV=_U]MZ>2C$DT8@1"_@Y/)]@?G+J1@1N.^UF:S6=KR5=A$%(S34+A8S(;O*= M48!!3$6$W4-+(O5MYNUU5N<9B9NXTEBJ9R#6D_V%R4719T0=#SH8P^,CC\YF M0!$+LO[DL'1RZ49B -BS62\3[&39N;Q[E4U[E49K$WJW4HM,-GC-;KG"VD3T MG!0YHR1M<&!8+?JBJT5ETY&G>HKX);NSVIA2\ G(!C4^FLR=4$14R M%[,DC_" \$@1\"-@BS+OY=ZUNUB[7\"7G>.(#GQ&7.;["):P&EL"_<+O(?6\ MY+L=R<[4%;Y/0\4ZR8>'%80L$FAXX=3KWUO.=>J6RDX]20&!+JG_]1;SRF;K M>RP!9&_<,QF!YON6J6:B^4;VZ<9Z3RB] "=;FCJ/%LS BR>@+65"8CE85DIL B!U\3Q8)Y\WS4=<$'D1(B(;: M!_4C"%%=$0>1G'6%]Z)PA^5:K&)$+)3B'H==B'<.Y,R?F$\G$ =7@NC(6T?Z MJ8KGFV^%G<_..PR_/W.?P3T(\\\/ XZ#]2>GTFSO-P]7,N^_EX(/G1OZ-9.:[VH%@WB(@79#D+\@6 M%" 5E,.38(FS!>( B?"LL]LSX?4M[.-MA=05XS%7ZFN0"7I#8JSW?U8<9]=] MTAN'OI@Q^>8"6?2KY$)4YW)9=GH9,+/DO9)"/F#F/+#*W@*?C5@T^%AJK-_L MZT1CB6Z^#)"=>IYD2MD_YY"@."\(;,W2R7Y]GW0%51'Y4<0^NZ?2(WT11Z-\ MG"NO+H:L(JWQ M):I9-^#+&?-.L?ED+N0-;69%07/E[*&S$)7D#+?NGDG))_ M8X+S7*[HT'C<%_-;*M+;LG3=J45<"6.K_ M'P^?E=G,N?^A=-)NU)O+.OM-X,-'6+EKF85UFU""(O.0^H1-F1M'_![+.1 ; MF-K;DI8AB:^K8FLQ!92&H-;L+%5&\.O'6.,AD')3T'_0P=6^#=WJ*;1[H;$< O<.]P_WEG>Q/#L' M/!<@O2N6]Q+NQ!0P]*@\0K7=:WS]) MZP \C)A[IQ?T: @( _P\9NT#,24#YHL)RA!OHJ0?MU.]"*YMA0RYC^Z%*_ U M$0/B/%S55'P<^Q$-F(B5/R,*S%,-9WH$^X 8 /NTU>JX@WT. :6*"#R(\XIC(JLY*U3IX;I5\4U5P9[Y1J5//U,.7Z^ZYNOQ: *)45+,& MC2@,NN M 1"R B'?]?8K^]L$WN\#MX/8+>#)P9_[VE-?YEI1WSACHVG!F M67,?=?%.BU:<1N+EYTJ^L VNTZE73XUX&9+U;P\:LX4HR].2X7UKO M<\-(+"^'PV= Y;6MHO$M6<6C*@HG0^Z:A;WK3T#.JP&M4,U9,L< XWG1Q\@:/2YKMO.Z(N#Y5 MZG46C9_+PK?FEZ1HGGHQK3\;0[-=]4K+[-\HQR[LEE6M8,R&#\T_$1"P![@Z M=\[U>Y,-:JO88DW&6,L+>+(//#D][WX=LUW$/ 119X5/*^8, M<>>Q ]\G-X I+JCRZ-^D2T,>49]\H?*.I1#NID9<7=B& M$>[ 6)G>@I8K)G-%@!, 0)&(6W(KQ20:(08-L:( M1(B[-$R&VNK3U[U>),1>L4" 7*<-Z<_#Z_O)PS_I9[OFT>VE90 ME6EGPP=T&==["PV#+RVPC$#MF0_I!*A]('1R$2NF6P%Y=AT'7ZS!]9XP<[@< M^:7'\F V.B@8ME1^JZN+$<&^,K-CPJ/646<+P' M,YOF+DTSFZSN5]=4CNE-2KHYRK4]S?CP0,*^(AUSUCGFOL8Q]F_XO+Q9_K2+ MH#L[A?;CL/&2_>"E#,X:,) 3X"Q_0F<*8QYTO7,\2B$9)*)"=KYKZ_^.DMF$ MTVRRZ?J,2HS!(YW6[3RRRKS9-R'LY*MK/UY>?^I=5[J7Y^>G5_U>)_GP-5?7 M'*>PO$;T1]"DY5K1\G:;LXB-DT!5K3>6MQIE.WNK MA#V829Y353L1_I%>U+ M\)FVO@6>CWQ.G6)7@)/67O4I%::#3528?J3HGV%D0!82#\4R%7%<)%)EQ$% M=9\!%L =-L96DU.I9;)T!)'LHG=&F37J1]TT=C<:SA$&@^3&_#%[T8I?UH!+]KP\JXPEFAF334.^^!/Q4=B#C"P<:OREJD%":J!3S$0QQXDO?76)_D M]6?)^7L@?[U-1("T?DUW$5FM_#OMS2+.AQ72LDJSXT+<9YHX+=-DB4&9R3^[ M+/X>JY-8?5BM.]]JK+[4UM6[UV[QU4/Q,H_UYPZ66KB+QR3 JP3*!@J!JX[H MK,Q"5Q_"I2*GM^#"=7QX=./J1DB^#(A]6T4>'&2B#P0)%:.G),:K@2]D%&-! M$(##1076K;.K@MJYH5L-!<(3/<6)W8%EW74Z?SS0A^\/,+5'A;7'*CF%[V&Z M57!Q7"S^1!&%9-@C(&\&OHMB067$!SPB[7;5V;X//<.X'P0FQ35!HRA>IQS( M37J1OTHKAF>@!H216"8\3=+:.2-6]<=-Y$FYJOO%2JTJ8O!"HFX[UB$O5CH. M>/,I96I6B!#2W'U^_' !-O9[W105PJW3^#96D77@CE:NI@:F=&QF/)CEQU=Q M"'A*:U&>E%X7^_Q"I3LR73;:B;Z"&#%@T8:#668'B]9_Q%62_4QY,='IH1O@G'8='T*Q:)N?G M78/XDHL> MD9&8L'L\;5 T@&1CF!;",3*,@6:(]*[!G0S8[$:O@6" [JY->.8@Y5%\@BC& M".*P\HOY #;B^PEF0>Z#64-2$,41T_ -%4=O?X9P32RD468[7FJ9V7:#>&9D M-S>;12Q?M@M0,(,!,SOZ/ ;4 T "C1HS:G9/4Y+ZR[G@QHQ%B6N0F&1)FP+H M-"];;JL_7.U>,,$%;5]HGEIR(/2Z#[ (RP#RE,%796J9!@ BJ);)Z?*L^?) M\:9AB(KA'\W'@>GBT26BN)V70I#V 3G]^_'6^E21# M%'2A^::'S5+T.@"LD%MKC'#6 9TIIZ\)F'"UD"-C1SZG ^YGS(!& M*(-$3'9X11Q'3\5I[-*]W<9>L?(:=[F2<0N\6F#*_'T!)N"D[Z'% PY"ZZ8] MPC!AQOMFO6$Y780RM4F=GPPCJU$8130*$4,,0K=4>KX]>(?]WK* 24C7%UY9 M +H7W,8 \9%LK7]F^ )PS"C:AM(TDR<15@P0ZC$Y5K:\DB\5/82,R_H94S'(#&"5/HD#$X$K,-;@ 19P M/.L9L7)B]O;.@/D<0GK^+4@?< MWJ_B%PAQ:2T*1$ \KC%()9:&UE-;W6>1M##B' M%=KY@9M'/)M86O(XDFZ*1ZLW.2VY/Y+U?X0V4 MD\_&6A(O"2ZNR!=LI:ILB\G_C@.6+V 5UPX6TOU&TG8>9PT04]D9:$2H%GLR M? 51:Z"+?_4BT3V%V(#E9)!;YJ<&0-@F35[%[%P"P%6NX@4 A-Z9')&F^:1& MGNE^1K@R _@JF(A+H?'1(R%.F<:HB[2KOY:J=>UCZQDIA(P9M!UK*$-0XRD.3'MLP/ MD54&OG#OGG0TH0"G6E749P\N1/49IS:>]&*OQP[[;)Q7VB8J: -/X12^,UBY MDH?)&T7G/L.JO-$;!Y===Z%V*)NN@*OD"DO M9^@H((/"U[)]HA$E^F6JN[CQQ?-L!F.K1F?:,1'\B40 ?^9W+?8RII/&V_?< M_C5R^_5^.>OLIXO3F]^N>_WGY#4O.EAPE5LHSJ\8/GFEI^# @1=#%J.+$YY) MELPKPO1**.!^X(39G8H;$ 9L1/UA4GO02:EM@'E/C$LQNCN0VTA(F*3W7PG@ M\I!M4=5;&I6M#^)6'5U>MYOBI_T'SD(M.&=DC55(Z=5 M6:0'KW.[ M"P I" !$ !D.#DT-38V9&5X.3DQ+FAT;W&]B5X#BW=5&TIJXO_X^1]KEU;'OS'4ZM].I0;N2 MSLMSSGG.H=W+R<=1KWMYT3_OE4O=R7 RNNA=_*MV>EIO=@_\5ZP?Y"^P[KOK M\\_LW8?!]>AZ_+;RU^5PJQ[Y\,_BY:4,[:+SIGXLDPKCD9PG.$#,;,5=IM19.0 ME5[W7>_BVT).I66D,>L>O.MU#VYZ&P)LG'Z(TW?DV1.GTOLEF9KTC$Z!XM_3 M8W]?(5G@3$56<)8;?OS ;L>#MY7YF].CXW9[WFRT&HV3H]/CDZ/#X_J7=$X[ M)V\KH^L/UY5MX[;JS=/#5ELF9[E3&O5VJ]UL-K'BS;RMZH:,AT'QTLOF %MZ<,:6970B6/U9QRI,'_^@U M>W7%3+@4(,6R.:L;RN6!3J=(%1Z %(K.TS@)_!!0,,C(H M+!>*>Q&IE,R9*'QD 4F1Q4R+2' C:CRP\IY;O%T\*<0=]P>%,,&")PDVR\2% MB\3!$%SS5,)X,ZC!@\P*QA.%^X99YPK(D%'JII;4B8:G'BMK BK2&&1@$ M(N%;X)%C"#GU)[#^,JCI1Q%=2M[,1;"*3?%%1=#<6>MI^;%G8TNY-'UP>W)0 MU $D: 0?!,[X2VD7[GE:Q$YQ4'5S&Q/?4NQPPLPU3^RV' )^8]WWUU>35>98 M8+5F4D"JDZ@E'%SIM1HU>*A[0._UF$J]]Q4TT("%P7DI?86#>!@Z; ")S>.? M=^R1.VC3+5O6\08IEPI%ZFR"U95])'R;3;] &[H,[KH3UL%*$1#)-OYN((I6 M:5$ T0E9-(%TQF0P0 ",.FLL%\+M W3QT4NPNBL&(+&-HBD2B(QJ$:B(E0S* M$2CP8;V@5(2DH=5?369)X11(D"NTB]!^6 M].)YX-[6 M6@5J7[V7L(W?42X]L>=*U?,\WVK5#D]:IT>GKU>'R"2(LM!9G$T)^8@^0P&6 MF=?X+.ZERDR$](O+PG6,WHH@@Q$H51(T+[Y1-IV[((VE,:3=JW49N+U895T\ MZ&?SS%@O4K/I2D_+G1**($)>4$AE3=>Q0'< <^%/RY;+9=V(H#Y7]W7V%Z*Z M7%KMK#*4N\#ZTA0H5[=R"5_6'L_J3,F%1\:E>C6U'*PY)-F[ZNH3:S8:S=89$S%,UV$BB'_]0N)8 M+TX=)OCQY72R0'J 8XPI> H+%5Y)E"5#>8,0W_!V)<,;0258ETMY*I0![.!2 M!_R\^>(T>ZCB($V%"5M\I2"4H5X:3B!SN,"59AVX*%+N.64A2OU?\," R;D+ M\!"Y)%@ ,_B/NZBZ(X+V1R]5AHHW)8A$?#G+(B@IE2Z LY7QL/PU(PH*:N<6 M'*Q\IE\+AF.,U_"A7'+W/RKCDRY[\Q(N [WO3U5FV2;)?X:QMU_BXDU:[;(= M%4;V(ER9*/#SW/AR+5U=@-T$S$C'@?, YJB9A=:X'I'-S8-@=R[P_D+ M0SB;^7CQL4?4%WC6N!G%D\A:2E>+<&WG^EYKE5O0KR-#.$7##(J"](4R))/T MLV]*\^[MIT?:^9/CG\_8O= .##4W@>@ DFC@TGONZ%Y>MPZ>E3$X*Z?*I?@JP6B#!5) M@]\Y^?QA(PZZ$D6\"G34\UQ_<#[\$WD_G_N52\S]VTU1FQXBL5U\1+Q7 F@I M1=:N39%;[FI3 =%$AT=+_F J*&('*5UR.09T_XV@;E6*<]U3:,&%U>3B_'_W622RB>ZFB7<4ANAA2.$W18MC_E'ZFB_X#?^ M2M>6[[$P[DK\++,9DK;'*L_;[C3BB2E*CO%S!\+4UCQLW4)M7.4/=:T#$7&: M8;@6P@$OSTIY_7N.7E\&3Q)V M7BSJ]_8R-5([*T1$MY>"_26S>.PUEQI7)B![&[@-W2@!@M#B\;#!TV8W.R?1_@S]VQX3%DA9GU4?+S?/#U%JNS[ M^4Q1@JG5"J7C_>0T2M/4G5.FM MEB%L1*FV>3(D\?U]2FK+P_&BZ$1F4VGU0 M'*H--+J8H7U3VFR O/,(YT,J3?A41FC65G.EUQ*F3H H$G-4+(,J^B)#=<-Y+DX1<<1S7#P=X&RT)L0S MB>+F>C+N)P]Y3!7;'4O=*%ES,$9-AJ^72_WU@!"MR9W/%L1O-$6G\[ ;_SHH M@LAE9C5S0X: 6/D(I7 P]'_2OX15@?11N)CD?,K#6N2^*^SG#<[]S-/C?PS! MV7MO@CP$ -]'N/T?OE1&H,)C01CY[R=7S4;MCV+J5#@VK[Q,N.+_&WC^S@\2 MCPQ1=L= A_[5S22)7;""V7)9S.^$V3[)&Q4EP[6J])>.6 ]F=L!%F,TSN439= MP@!D2 +^A+XO M?K2>W4\]]Z.=Y^R_U&H]8\;1P6 M>>W[K0) >7W^&8ON_T[X#U!+ 0(4 Q0 ( !F'7EGECO;V/@, %<+ 1 M " 0 !C86QC+3(P,C0Q,#,P+GAS9%!+ 0(4 Q0 ( M !F'7ED17]!MK@8 *9) 5 " 6T# !C86QC+3(P,C0Q M,#,P7VQA8BYX;6Q02P$"% ,4 " 9AUY9PD?@?^$$ '+@ %0 M @ %."@ 8V%L8RTR,#(T,3 S,%]P&UL4$L! A0#% @ M&8=>6:S(:(PJ%@ "( X ( !8@\ &0X.30U-C9D.&LN M:'1M4$L! A0#% @ &8=>6:0'KW.["P I" !$ ( ! KN"4 &0X.30U-C9D97@Y.3$N:'1M4$L%!@ % 4 0 $ *(Q $! end XML 18 d894566d8k_htm.xml IDEA: XBRL DOCUMENT 0001534133 2024-10-30 2024-10-30 NASDAQ false 0001534133 8-K 2024-10-30 CalciMedica, Inc. DE 001-39538 45-2120079 505 Coast Boulevard South Suite 307 La Jolla CA 92037 (858) 952-5500 false false false false Common Stock, $0.0001, par value per share CALC true false